Schizophrenia and related disorders affect a sizable proportion of any population. Neuroleptic (antipsychotic) medications are the primary treatment for these disorders. Neuroleptic medications are associated with a variety of side effects including tardive dyskinesia. Dyskinesia is a disfiguring movement disorder of the orofacial region that can be tardive (having a slow or belated onset). Tardive dyskinesia is difficult to treat, despite experimentation with several treatments. One side effect of psychoactive medications is tardive dyskinesia (TD), a movement disorder similar to Tourette syndrome Calcium channel blockers (diltiazem, nifedipine, nimodipine, verapamil) have been among these experimental treatments. To determine the effects of calcium-channel blocker drugs (diltiazem, nifedipine, nimodipine, verapamil) for treatment of neuroleptic, researchers randomized clinical trials comparing calcium-channel blockers with placebo, no intervention or any other intervention for people with both tardive dyskinesia and schizophrenia or serious mental illness. The effects of calcium-channel blockers for antipsychotic induced tardive dyskinesia are unknown. Their use is experimental and should only be given in the context of well designed randomized clinical trials. Symptoms of tardive dyskinesia can develop and persist long after use of the medication causing the disorder has been discontinued. Tardive dyskinesia can appear similar to other types of disorders, most notably Tourette's syndrome.
Essali, A., Deirawan, H., Soares-Weiser, K., & Adams, C. (2011). Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews, (11),
No comments:
Post a Comment